•Compared with the first nine months of 2018 (on a like-for-like basis):
?Revenues up 26%, operating profit up 38%, net profit up 73%
•Compared with the previous quarter ended 30 June 2019:
?Revenues up 7%, operating profit up 46%, net profit up 52% (after additional €2.5 million provision for contingent consideration)
?Maintained cash position despite paying a €17.9m upfront to secure the rights to leniolisib from Novartis
•Good progress in expanding and extending the pipeline:
?· Strategic investment in the license from Novartis of the new leniolisib (CDZ173) program, the first new program from outside the Company’s platform
?· Initiation of the first clinical study of RUCONEST® in pre-eclampsia

Leiden, the Netherlands – 24 October 2019

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2019.